Switch theme
Sign up to access all valuation multiples
Vistin Pharma ASA is a Norway based pharmaceutical company. It is principally engaged in the business activity of producing active pharmaceutical ingredients (APIs) and solid dosage forms for the pharmaceutical industry. The company has two business segments namely Pharmaceuticals and Energy Trading. The group has operations in Norway, Germany, Switzerland, Great Britain, Algeria and other countries.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vistin Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vistin Pharma achieved revenue of $40.6M and an EBITDA of $10.8M.
Vistin Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vistin Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $41.2M | $40.6M | XXX | XXX | XXX |
| Gross Profit | $8.3M | $19.1M | XXX | XXX | XXX |
| Gross Margin | 20% | 47% | XXX | XXX | XXX |
| EBITDA | $7.4M | $10.8M | XXX | XXX | XXX |
| EBITDA Margin | 18% | 26% | XXX | XXX | XXX |
| Net Profit | -$0.4M | $4.3M | XXX | XXX | XXX |
| Net Margin | -1% | 11% | XXX | XXX | XXX |
| Net Debt | $4.1M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Vistin Pharma's stock price is NOK 23 (or $2).
Vistin Pharma has current market cap of NOK 1.0B (or $97.3M), and EV of NOK 1.0B (or $95.0M).
See Vistin Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $95.0M | $97.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Vistin Pharma has market cap of $97.3M and EV of $95.0M.
Vistin Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Vistin Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vistin Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $95.0M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 8.8x | XXX | XXX | XXX |
| P/E | 16.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 15.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVistin Pharma's NTM/LTM revenue growth is n/a
Vistin Pharma's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Vistin Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vistin Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vistin Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 46% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 45% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vistin Pharma acquired XXX companies to date.
Last acquisition by Vistin Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Vistin Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vistin Pharma founded? | Vistin Pharma was founded in 2015. |
| Where is Vistin Pharma headquartered? | Vistin Pharma is headquartered in Norway. |
| How many employees does Vistin Pharma have? | As of today, Vistin Pharma has 77 employees. |
| Who is the CEO of Vistin Pharma? | Vistin Pharma's CEO is Mr. Magnus Tolleshaug. |
| Is Vistin Pharma publicy listed? | Yes, Vistin Pharma is a public company listed on OSL. |
| What is the stock symbol of Vistin Pharma? | Vistin Pharma trades under VISTN ticker. |
| When did Vistin Pharma go public? | Vistin Pharma went public in 2015. |
| Who are competitors of Vistin Pharma? | Similar companies to Vistin Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Vistin Pharma? | Vistin Pharma's current market cap is $97.3M |
| What is the current revenue growth of Vistin Pharma? | Vistin Pharma revenue growth between 2023 and 2024 was -1%. |
| Is Vistin Pharma profitable? | Yes, Vistin Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
